Results 171 to 180 of about 3,591 (202)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

Annals of Oncology, 2018
A Dechaphunkul, M Aapro
exaly  

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

Expert Opinion on Drug Safety, 2020
Andrea Antonuzzo, Paolo Bossi, Daniela Musio   +2 more
exaly  

Delayed CINV

2010
openaire   +1 more source

Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey

Cancer Reports, 2018
Matti Aapro
exaly  

Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers

Supportive Care in Cancer, 2014
Aminah Jatoi
exaly  

Barriers and opportunities in CINV management

2016
openaire   +1 more source

Personalisierte CINV-Prophylaxe

Im Fokus Onkologie
openaire   +1 more source

Rolapitant approved by FDA for CINV

Reactions Weekly, 2015
openaire   +1 more source

Aprepitant not cost effective for prevention of CINV

Inpharma Weekly, 2007
openaire   +2 more sources

CINV: still troubling patients after all these years

Supportive Care in Cancer, 2018
Matti Aapro
exaly